Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Sponsor: Stemline Therapeutics, Inc.
Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Official title: A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-01-10
Completion Date
2028-06-02
Last Updated
2026-05-26
Healthy Volunteers
No
Conditions
Interventions
MEN2501
Oral tablet
Locations (6)
Highlands Oncology Group
Springdale, Arkansas, United States
Yale University
New Haven, Connecticut, United States
Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
NEXT Virginia
Fairfax, Virginia, United States